Your Account
Cancer Chemoprevention
Volume 2: Strategies for Cancer Chemoprevention
This book is currently unavailable – please contact us for further information.
(To see other currencies, click on price)
Paperback / softback
Add to basket  


Main description:

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development—those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can “reasonably predict” clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.

Back cover:

Much progress has been made in discovering and developing agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. In Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, leading chemopreventives investigators comprehensively describe the exciting methodologies that are accelerating progress in the chemoprevention field and review the state of clinical development of preventive agents in the major human cancer target organs. The authors provide sound guidelines for cancer chemopreventive drug development, detailing general strategies and methods for drug discovery, preclinical efficacy, characterization of precancers, safety evaluation of clinical cohorts, and clinical trial design. Additional chapters address strategies for and the status of chemopreventive agent development in multiple myeloma and cancers of the prostate, breast, lung, colon, bladder, head and neck, esophagus, pancreas, ovary, endometrium, cervix, skin, and liver. The emphasis is on documenting the characterization and application of reliable biomarkers during chemopreventive drug development. Highlights include an elegant approach to identifying chemopreventive agents in natural products, the development of preclinical models for evaluating potential chemopreventive agents, the genomics and proteomics of potential applications, and approaches for determining which populations will likely benefit from chemopreventive intervention. A companion volume, Promising Cancer Chemopreventive Agents, comprehensively surveys those agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. A value-added compact disk containing a companion ebook version of Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention is included for downloading and use in the reader's PC or PDA.

Up-to-date and highly practical, Cancer Chemoprevention, Volumes 1 & 2, offer oncologists, pharmacologists, medicinal chemists, and toxicologists a comprehensive reference survey on the identification of those promising cancer chemopreventive agents that will help stimulate further research and the development of novel approvable drugs.


Part I. Chemopreventive Agent Development Science

Characterization of Natural Product Chemopreventive Agents
John M. Pezzuto, Jerome W. Kosmeder II, Eun-Jung Park, Sang Kook Lee, Muriel Cuendet, Joell Gills, Krishna Bhat, Simonida Grubjesic, Hye-Sung Park, Eugenia Mata-Greenwood, YingMeei Tan, Rong Yu, Daniel D. Lantvit, and A. Douglas Kinghorn

Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs
Vernon E. Steele, Ronald A. Lubet, and Richard C. Moon

Potential Use of Transgenic Mice in Chemoprevention Studies
Ronald A. Lubet, Jeffrey Green, Vernon E. Steele, and Ming You

Modeling Human Colorectal Cancer in Mice for Chemoprevention Studies
Martin Lipkin and Sergio A. Lamprecht

Pathology of Incipient Neoplasia
Donald Earl Henson and Jorge Albores-Saavedra

Quantitative Nuclear Grade: Clinical Applications of the Quantitative Measurement of Nuclear Structure Using Image Analysis
Robert W. Veltri, Alan W. Partin, and M. Craig Miller

Enabling Discovery Through Online Cancer Genome Databases and Analytic Tools
Robert L. Strausberg and Gregory J. Riggins

Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention
Melissa A. Troester and Charles M. Perou

Clinical Applications of Proteomics
Emanuel F. Petricoin III and Lance A. Liotta

Bioinformatics and Whole-Genome Technologies
Richard Simon

Models of Absolute Risk: Uses, Estimation, and Validation
Mitchell H. Gail

Genetic Polymorphisms and Risk Assessment for Cancer Chemoprevention
Sonia de Assis and Peter G. Shields

Design Issues in Prostate Cancer Chemoprevention Trials: Lessons From the Prostate Cancer Prevention Trial
Ian M. Thompson and Charles A. Coltman Jr.

Recruitment Strategies for Cancer Prevention Trials
Paul P. Carbone, Karen Sielaff, Mary Hamielec, and Howard Bailey

Part II. Cancer Chemoprevention at Major Cancer Target Sites

Prostate Cancer Prevention
William G. Nelson, Angelo M. de Marzo, and Scott M. Lippman

Use of PSA to Evaluate Risk and Progression of Prostate Cancer
Bulent Akduman, Abelardo Errejon, and E. David Crawford

Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs
Carol J. Fabian, Bruce F. Kimler, Matthew S. Mayo, William E. Grizzle, Shahla Masood, and Giske Ursin

Ductal Lavage: Its Role in Breast Cancer Risk Assessment and Risk Reduction
Joyce O'Shaughnessy and Andrea Decensi

Counteracting Estrogen as Breast Cancer Prevention
Kathrin Strasser-Weippl and Paul E. Goss

Chemoprevention of Colorectal Cancer: Clinical Strategies
Monica M. Bertagnolli and Stanley R. Hamilton

Screening in Risk Evaluation and Prevention of Colorectal Cancer
Bernard Levin

Strategies in Lung Cancer Chemoprevention
Edward S. Kim, Faye M. Johnson, Waun Ki Hong, and Fadlo R. Khuri

Lung Cancer Chemoprevention: An Opportunity for Direct Drug Delivery
James L. Mulshine and Luigi M. De Luca

Bladder Cancer: Clinical Strategies for Cancer Chemoprevention
H. Barton Grossman, Anita L. Sabichi, and Yu Shen

Barrett's Esophagus: Strategies for Cancer Prevention
Brian J. Reid

Endoscopic Detection of Esophageal Neoplasia
Brian C. Jacobson and Jacques Van Dam

Chemoprevention Strategies for Esophageal Squamous Cell Carcinoma
Paul J. Limburg, Philip R. Taylor, and Sanford M. Dawsey

Head and Neck
Chemoprevention of Upper Aerodigestive Tract Cancer: Clinical Trials and Future Directions
Fadlo R. Khuri, Edward S. Kim, and Waun Ki Hong

Chemoprevention of Oral Cancer: Ri


ISBN-13: 9781627038171
Publisher: Springer (Humana Press)
Publication date: November, 2014
Pages: 576
Weight: 1402g
Availability: POD
Subcategories: Oncology
Related books
From the same series


Average Rating 

"...comprehensive review of the literature concerning current and future cancer chemoprevention strategies... provide(s) a basis for future developments." - The Annals of Pharmacology

"...a good reference source for students and experts alike who are interested in evaluating cancer risk, strategies available to try to prevent certain cancers developing and how the incidence of cancer can be reduced b the use of therapeutic agents. -Newletter of the British Toxicology Society